483
GlaxoSmithKline BiologicalsGlaxoSmithKline Biologicals – FDA 483, Mar 12, 2024
Record Details
GlaxoSmithKline Biologicals in Saint-Amand-Les-Eaux, France, was inspected regarding its Shingrix vaccine manufacturing. The inspection revealed significant deficiencies including delayed investigation of vial defects, inadequate equipment cleaning procedures, and failures in both reserve sample examination and timely adverse event reporting. These issues indicate a lack of thorough quality control and compliance with regulatory reporting requirements.
View Company Profile
ID · 132ad59c-5f34-44cf-a334-a1cf5c633f04
Other documents for GlaxoSmithKline Biologicals
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.